Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.459
Buy
RSI(14)
64.006
Neutral
STOCH(KDJ)(9,3,3)
78.062
Neutral
ATR(14)
1.201
Low Volatility
CCI(14)
74.667
Neutral
Williams %R
13.180
Overbought
TRIX(12,20)
0.552
Sell
StochRSI(14)
0.000
Sell
Phibro Animal Health Corp
PAHC38.405USD
+6.205+19.27%
Market hours （ET）Quotes delayed by 15 min
1.56BMarket Cap
48.96P/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-27Key Insights
The company's fundamentals are relatively healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Hold.Despite a very weak market performance, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
4
analysts
Hold
Current Rating
23.000
Target Price
-29.53%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 804.72%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 804.72%.
Fairly Valued
The company’s latest is 41.03, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.85M shares, decreasing 12.99% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.54M shares of this stock.
Financial Health
Currency: USD Updated：2025-08-27The company's current financial score is 7.74, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 347.82M, representing a year-over-year increase of 32.14%, while its net profit experienced a year-over-year increase of 148.42%.
Score
Financials
7.20
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.93
Operational Efficiency
7.50
Growth Potential
7.07
Shareholder Returns
8.98
Valuation Dimension
Currency: USD Updated：2025-08-27The company’s current valuation score is 3.60, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 41.03, which is 7.32% below the recent high of 44.03 and 52.29% above the recent low of 19.58.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 28/690
No Data
Forecast
Currency: USD Updated：2025-08-27The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Phibro Animal Health Corp is 24.00, with a high of 26.00 and a low of 19.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
4
analysts
Hold
Current Rating
23.000
Target Price
-29.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
178
Total
5
Median
8
Average
Company name
Ratings
Analysts
Phibro Animal Health Corp
PAHC
4
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
34
Amgen Inc
AMGN
33
Eli Lilly and Co
LLY
29
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-27The company’s current price momentum score is 9.63, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 34.91 and the support level at 27.54, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
32.158
Buy
MA10
31.627
Buy
MA20
29.686
Buy
MA50
28.713
Buy
MA100
25.009
Buy
MA200
23.817
Buy
Institutional Confidence
Currency: USD Updated：2025-08-27The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 102.34%, representing a quarter-over-quarter decrease of 3.83%. The largest institutional shareholder is The Vanguard, holding a total of 1.54M shares, representing 7.58% of shares outstanding, with 2.07% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
Acadian Asset Management LLC
Dimensional Fund Advisors, L.P.
Geode Capital Management, L.L.C.
Castleknight Management LP
Nuveen LLC
1
2
Risk Assessment
Currency: USD Updated：2025-08-27The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 4.69, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.87
VaR
+3.82%
240-Day Maximum Drawdown
+36.96%
240-Day Volatility
+45.33%
Return
Best Daily Return
60 days
+6.79%
120 days
+14.75%
5 years
+31.81%
Worst Daily Return
60 days
-5.09%
120 days
-7.67%
5 years
-18.52%
Sharpe Ratio
60 days
+3.34
120 days
+1.57
5 years
+0.55
Risk Assessment
Maximum Drawdown
240 days
+36.96%
3 years
+41.42%
5 years
+68.12%
Return-to-Drawdown Ratio
240 days
+1.55
3 years
+1.11
5 years
+0.22
Skewness
240 days
+0.76
3 years
+1.82
5 years
+1.45
Volatility
Realised Volatility
240 days
+45.33%
5 years
+44.35%
Standardised True Range
240 days
+2.85%
5 years
+2.24%
Downside Risk-Adjusted Return
120 days
+257.57%
240 days
+257.57%
Maximum Daily Upside Volatility
60 days
+29.57%
Maximum Daily Downside Volatility
60 days
+25.59%
Liquidity
Average Turnover Rate
60 days
+0.69%
120 days
+0.65%
5 years
--
Turnover Deviation
20 days
+28.81%
60 days
+40.04%
120 days
+33.45%
Peers
Currency: USD Updated：2025-08-27Phibro Animal Health Corp
PAHC
7.07 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Zoetis Inc
ZTS
7.56 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.55 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.52 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
ACADIA Pharmaceuticals Inc
ACAD
7.52 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
